Bicara Therapeutics (NASDAQ:BCAX) CFO Ivan Hyep Sells 6,415 Shares

Bicara Therapeutics Inc. (NASDAQ:BCAX) CFO Ivan Hyep sold 6,415 shares of the business’s stock in a transaction that occurred on Thursday, October 9th. The shares were sold at an average price of $18.23, for a total transaction of $116,945.45. Following the completion of the sale, the chief financial officer directly owned 145,355 shares in the company, valued at $2,649,821.65. This trade represents a 4.23% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the SEC, which is accessible through this hyperlink.

Ivan Hyep also recently made the following trade(s):

• On Tuesday, October 7th, Ivan Hyep sold 18,244 shares of Bicara Therapeutics stock. The shares were sold at an average price of $18.22, for a total transaction of $332,405.68.
• On Wednesday, October 8th, Ivan Hyep sold 5,627 shares of Bicara Therapeutics stock. The shares were sold at an average price of $18.21, for a total transaction of $102,467.67.
• On Monday, October 6th, Ivan Hyep sold 6,514 shares of Bicara Therapeutics stock. The shares were sold at an average price of $18.17, for a total transaction of $118,359.38.

Bicara Therapeutics Stock Performance

Shares of BCAX stock opened at $17.78 on Friday. The stock has a market capitalization of $970.97 million and a P/E ratio of -5.61. The company has a 50 day moving average price of $12.51 and a 200 day moving average price of $11.87. Bicara Therapeutics Inc. has a fifty-two week low of $7.80 and a fifty-two week high of $28.09.

Bicara Therapeutics (NASDAQ:BCAX) last announced its quarterly earnings data on Tuesday, August 12th. The company reported ($0.50) earnings per share for the quarter, beating analysts’ consensus estimates of ($0.54) by $0.04. On average, research analysts forecast that Bicara Therapeutics Inc. will post -2.59 EPS for the current fiscal year.

Institutional Inflows and Outflows

Several large investors have recently modified their holdings of BCAX. XTX Topco Ltd boosted its holdings in shares of Bicara Therapeutics by 4.1% in the 1st quarter. XTX Topco Ltd now owns 28,453 shares of the company’s stock valued at $371,000 after buying an additional 1,119 shares in the last quarter. Legal & General Group Plc boosted its holdings in shares of Bicara Therapeutics by 64.1% in the 2nd quarter. Legal & General Group Plc now owns 3,156 shares of the company’s stock valued at $29,000 after buying an additional 1,233 shares in the last quarter. California State Teachers Retirement System acquired a new position in shares of Bicara Therapeutics in the 4th quarter valued at $25,000. Ameritas Investment Partners Inc. boosted its holdings in shares of Bicara Therapeutics by 73.0% in the 2nd quarter. Ameritas Investment Partners Inc. now owns 3,493 shares of the company’s stock valued at $32,000 after buying an additional 1,474 shares in the last quarter. Finally, Bank of New York Mellon Corp boosted its holdings in shares of Bicara Therapeutics by 4.8% in the 1st quarter. Bank of New York Mellon Corp now owns 42,192 shares of the company’s stock valued at $550,000 after buying an additional 1,924 shares in the last quarter.

Wall Street Analyst Weigh In

A number of research analysts recently weighed in on BCAX shares. Piper Sandler started coverage on shares of Bicara Therapeutics in a report on Monday, August 18th. They issued an “overweight” rating and a $36.00 price objective for the company. Wedbush reiterated an “outperform” rating and set a $30.00 price target on shares of Bicara Therapeutics in a report on Tuesday, August 12th. Weiss Ratings reiterated a “sell (e+)” rating on shares of Bicara Therapeutics in a report on Saturday, September 27th. Finally, HC Wainwright lowered their price target on shares of Bicara Therapeutics from $41.00 to $40.00 and set a “buy” rating for the company in a report on Friday, August 22nd. One investment analyst has rated the stock with a Strong Buy rating, five have given a Buy rating, one has assigned a Hold rating and one has issued a Sell rating to the company’s stock. Based on data from MarketBeat, the stock currently has a consensus rating of “Moderate Buy” and an average target price of $31.86.

About Bicara Therapeutics

Bicara Therapeutics Inc, a clinical-stage biopharmaceutical company, develops bifunctional therapies for solid tumors. Its lead program is ficerafusp alfa, a bifunctional antibody that combines an epidermal growth factor receptor (EGFR) directed monoclonal antibody with a domain that binds to human transforming growth factor beta (TGF-b) for the treatment of solid tumors.